Factual and Procedural Background
This opinion concerns an application by the Plaintiff, mother of XY, seeking a legal declaration that she and the Defendant, XY's father, have the authority to consent to puberty blocker treatment ("PBs") on behalf of XY. The application arises in the context of the Divisional Court decision in Bell v The Tavistock and Portman NHS Foundation Trust and Ors [2020] EWHC 3274 (Admin) ("Bell"), which addressed whether parental consent alone suffices for PB treatment or whether court approval is required.
The Second Respondent is Company A, which operates the Gender Identity Development Service ("GIDS") commissioned by NHS England to provide specialist care for children and young people with Gender Dysphoria. The Third Respondent is Company B, providing pediatric and adolescent endocrinology services in conjunction with GIDS.
XY, born male and now aged 15, socially transitioned and legally changed name, has been receiving PBs since July 2019 following assessments by GIDS and Company B. XY's parents delayed starting treatment until puberty commenced, having researched PBs extensively and taken a cautious approach. XY has been assessed as competent to consent by clinicians, but no fresh competence assessment has been made since Bell.
Following Bell, NHS England amended the Service Specification requiring court applications for continuing PB treatment post-review, but a stay was granted on this requirement for existing patients. XY's GP has continued prescribing PBs with uncertainty about ongoing consent legality, prompting this application for clarity.
The Court was assisted by Cafcass acting as Advocate and considered submissions from all parties. The central questions posed by Sir James Munby in an interlocutory judgment were whether the parents retain legal ability to consent to PB treatment for XY and whether PBs fall into a special category of medical treatment requiring court authorization or application as good practice.
Legal Issues Presented
- Do the parents retain the legal ability to consent to puberty blocker treatment on behalf of XY?
- Does the administration of puberty blockers constitute a "special category" of medical treatment requiring either mandatory court authorization or, as a matter of good practice, court approval?
Arguments of the Parties
Applicant's Arguments
- The Plaintiff and Defendant contend that they retain parental responsibility and the right to consent to PB treatment for XY.
- They emphasize their careful and informed approach to the treatment and argue that parental consent should suffice without court involvement.
Second and Third Respondents' Arguments
- Company A and Company B acknowledge the importance of parental consent but highlight uncertainty post-Bell regarding its sufficiency for ongoing treatment.
- They support continuation of PBs for existing patients on parental consent pending clinical review but seek clarity on the legal position.
- They rely on the regulatory and oversight framework as appropriate safeguards rather than court authorization.
Cafcass' Position
- Cafcass assisted the Court but did not undertake a best interests assessment due to lack of invitation to act as Guardian for XY.
- Raised the possibility of adjourning the case pending the Court of Appeal decision in Bell, but parties opposed adjournment.
Table of Precedents Cited
| Precedent |
Rule or Principle Cited For |
Application by the Court |
| Bell v The Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274 (Admin) |
Nature of puberty blockers; experimental treatment; legal framework for consent; Gillick competence requirements. |
The Court considered Bell binding and agreed with its analysis regarding the nature and complexity of PB treatment and the competence issues involved. |
| Gillick v West Norfolk and Wisbech Health Authority [1986] AC 112 |
Defines Gillick competence: when a child has sufficient understanding to consent to medical treatment independently of parents. |
The Court applied Gillick principles to assess parental concurrent consent rights and the child's competence. |
| Re R (A Minor) (Wardship Consent to Treatment) [1992] Fam 11 |
Parental consent can be concurrent with competent child's consent; parents retain right to consent even if child is Gillick competent. |
Supported the Court's conclusion that parents retain a concurrent right to consent unless the child objects. |
| Re W (A Minor) (Medical Treatment Courts Jurisdiction) [1993] Fam 64 |
Clarifies the scope of parental consent rights vis-à-vis competent child's consent; legal "flak jacket" analogy for consent. |
Reinforced the concept of concurrent consent sources protecting medical practitioners. |
| Re X (no 2) [2021] EWHC 65 |
Court's power to override refusal of treatment by competent child in certain circumstances. |
Did not advance the issue of concurrent parental consent but confirmed the Court's protective role. |
| Re D (A Minor) (Wardship Sterilisation) [1976] 1 All ER 326 |
Non-therapeutic sterilisation of a child requires Court authorization; special category of treatment. |
Identified as an exceptional case where court approval is legally required. |
| Re B (A Minor) (Wardship Sterilisation) [1987] 2 All ER 206 |
Confirmed that sterilisation of minors requires High Court leave; court's protective jurisdiction. |
Used to illustrate the limited scope of treatments requiring mandatory court approval. |
| F v West Berkshire Health Authority [1990] 2 AC 1 |
For adults lacking capacity, court involvement in sterilisation is highly desirable as good practice. |
Provided factors to consider when deciding if court authorization is needed for serious medical procedures. |
| Re E (A Minor) (Medical Treatment) [1991] 2 FLR 585 |
Parents can validly consent to therapeutic sterilisation of a minor; no court approval required if therapeutic. |
Distinguished therapeutic from non-therapeutic cases; relevant to parental consent scope. |
| Re GF (Medical Treatment) [1992] 1 FLR 293 |
Therapeutic operations may be lawfully carried out with parental consent without court declaration. |
Supported parental consent sufficiency in therapeutic contexts. |
| Re S (Sterilisation Patient's Best Interests) [2000] 2 FLR 389 |
Court to consider best interests and medical opinion where multiple treatments exist; court application advised near boundary cases. |
Emphasized cautious application of court involvement; relevant to good practice considerations. |
| NHS Trust v Y [2019] AC 978 |
Decisions to withdraw clinically assisted nutrition and hydration do not require court authorization as a legal requirement, but court guidance is good practice. |
Used to analogize the distinction between legal requirements and best practice in medical treatment decisions. |
| Simms v Simms [2002] Fam 83 |
Parental consent can be valid for experimental medical treatment of children. |
Referenced but found less helpful due to differences in clinical and ethical context of PBs. |
| UCLH v KG [2018] EWCOP 29 |
Parental consent valid for experimental treatment in children under certain conditions. |
Similar to Simms; court found it less applicable to PB treatment context. |
| Briggs [2017] EWCA Civ 1169 |
Court involvement not required in all cases of withdrawal of life-sustaining treatment when parties agree. |
Supported caution against blanket court involvement requirements. |
| M v A Hospital [2018] EWCOP 19 |
Urged against rigid court application rules; emphasized case-specific approach. |
Reinforced flexible approach to court involvement. |
| Re Jamie [2013] Fam CAFC 110 (Australia) |
Parents can consent to PB treatment; no special category requiring court approval for Stage 1 treatment. |
Considered persuasive but with a different approach to PBs than Bell. |
| Re Kelvin [2017] CAFC 258 (Australia) |
Stage 2 treatment (cross-sex hormones) requires court approval; emphasized parental role in decision-making. |
Weighted as relevant comparative authority supporting parental decision-making. |
Court's Reasoning and Analysis
The Court began by acknowledging the binding nature of Bell and its detailed analysis of puberty blockers, including their experimental nature, uncertain long-term effects, and the complex ethical and identity-related issues they raise. The Court emphasized that Bell did not address parental consent and that this case raised distinct legal questions.
On the first issue, the Court reaffirmed the fundamental role of parents under the Children Act 1989 and relevant case law, emphasizing that parental responsibility includes the right to consent to medical treatment. It examined the interplay between parental rights and Gillick competence, concluding that parents retain a concurrent right to consent even if the child is Gillick competent, provided they do not seek to override the child’s decision. This position was supported by authoritative case law, particularly Re R and Re W, and the reasoning of Lord Donaldson MR. The Court rejected the notion that parental consent disappears upon the child achieving competence, noting that parental rights serve to protect the child’s best interests when the child cannot or does not make a decision.
Regarding the second issue, the Court analyzed whether puberty blockers fall within a special legal category requiring court authorization. It reviewed the limited precedents mandating court involvement, notably cases involving non-therapeutic sterilization of minors, and distinguished these from the present case where parents consent and clinicians agree. The Court found no broad legal requirement for court approval of puberty blockers, recognizing that court involvement is appropriate in finely balanced, disputed, or ethically complex cases, but not as a general rule.
The Court considered regulatory and oversight frameworks, including NHS England’s Service Specification, the Care Quality Commission, professional bodies, and the ongoing Cass Review, as appropriate mechanisms to safeguard children’s interests rather than court intervention. It acknowledged the unique ethical challenges and polarized clinical views surrounding PBs but concluded these concerns are better addressed via regulation and clinical safeguards than by removing parental consent rights.
The Court noted concerns about "reverse pressure" from children on parents to consent but found no evidence of such pressure in this case. It emphasized that if clinicians suspect undue pressure or disagreement, those cases should be brought to court, but this does not justify a general rule requiring court authorization for all PB treatment.
In sum, the Court balanced the rights and duties of parents, the competence and autonomy of the child, and the nature of PB treatment, concluding that parental consent remains legally valid and that PBs do not constitute a special category of treatment mandating court authorization or application as a matter of good practice.
Holding and Implications
The Court held that the parents of XY retain the legal ability to consent to puberty blocker treatment on behalf of XY, regardless of whether XY is Gillick competent, provided the parents do not seek to override XY’s decision.
Furthermore, the Court determined that puberty blockers do not fall within a special category of medical treatment requiring mandatory court authorization or court application as a matter of good practice where parents and clinicians agree on treatment.
The direct effect of this decision is to clarify that parental consent remains valid and sufficient for the administration of puberty blockers to children with Gender Dysphoria under the current circumstances, providing legal certainty for clinicians and families. The Court emphasized that individual cases involving disagreement, finely balanced decisions, or concerns about pressure or competence should still be brought before the Court.
This ruling does not establish new precedent altering the role of courts in medical decisions generally but affirms the central role of parental responsibility and the sufficiency of parental consent in this context.